Market Overview

Credit Suisse Believes Top Line Growth Matters More Than Margins For Stericycle

Share:
Related SRCL
After-Hours Recap: April In Review, Friday Index Movers & After-Hours Runners
Mid-Afternoon Market Update: NASDAQ Down Over 1%; SkyWest Shares Jump On Earnings Beat

In a report published Monday, Credit Suisse analyst Hamzah Mazari reiterated an Outperform rating and $140.00 price target on Stericycle (NASDAQ: SRCL).

In the report, Credit Suisse noted, “We believe that operating leverage given lack of infrastructure pre-PSC deal should lead to much higher than expected earnings power over the next 12-16 months. Recall that SRCL can run StrongPak through PSC infrastructure and cut out third party treatment/disposal costs (i.e. had 1 Part B facility vs 13 post deal) in addition to better optimizing route density/logistics. Our sense is that 12 cents of 2015 full year EPS accretion is low based on our channel checks and past environmental deals.”

Stericycle closed on Thursday at $119.23.

Latest Ratings for SRCL

DateFirmActionFromTo
May 2016Imperial CapitalMaintainsIn-line
Apr 2016Stifel NicolausDowngradesBuyHold
Apr 2016Raymond JamesDowngradesOutperformMarket Perform

View More Analyst Ratings for SRCL
View the Latest Analyst Ratings

Posted-In: Credit Suisse Hamzah MazariAnalyst Color Reiteration Analyst Ratings

 

Related Articles (SRCL)

View Comments and Join the Discussion!